T-cell surface molecules

T-cell surface molecules comprise a diverse array of proteins expressed on the plasma membrane of T lymphocytes that facilitate communication between the immune cell and its environment (Janeway et al., 2001). This broad category includes the T-cell receptor (TCR) complex for antigen recognition, co-receptors such as CD4 and CD8 that stabilize MHC interactions, and a variety of co-signaling receptors that either promote (e.g., CD28, OX40) or inhibit (e.g., PD-1, CTLA-4) T-cell activation (Abbas et al., 2018; Chen & Flies, 2013). These molecules are fundamental to the adaptive immune response, governing the development, proliferation, and effector functions of T cells (Zhu et al., 2011). In clinical medicine, specific members of this group are primary targets for immunotherapy; for instance, checkpoint inhibitors targeting PD-1 or CTLA-4 have revolutionized cancer treatment, while agents targeting CD3 or CD28 are used to manage autoimmunity and organ transplant rejection (Sharma & Allison, 2015). Because the term "T-cell surface molecules" refers to a collective class rather than a single molecular entity, it is considered a functional grouping rather than a specific therapeutic target (Meyaard, 2010). Therapeutic strategies often involve modulating these surface proteins to either enhance immune surveillance against tumors or suppress pathological immune responses in autoimmune diseases (Waldmann, 2003).

Other names

T-cell markersT-cell antigensCluster of Differentiation (CD) antigens on T-cellsT-lymphocyte surface proteins

Drugs targeting these molecules act through various mechanisms: checkpoint inhibition (e.g., blocking PD-1 or CTLA-4 to enhance anti-tumor immunity), co-stimulation blockade (e.g., preventing CD28-B7 interaction to suppress T-cell activation), T-cell depletion (e.g., targeting CD3 or CD52 to reduce lymphocyte counts), or direct T-cell modulation (e.g., CD3 agonism or IL-2 receptor blockade).